KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) announced the CHMP of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA, the company's anti-PD-1 therapy, as
SOUTH SAN FRANCISCO (dpa-AFX) - The US Food and Drug Administration has approved Roche's (RHHBY) Tecentriq or atezolizumab as adjuvant treatment, following surgery and platinum-based chemotherapy
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting Approval is based on the Phase III IMpower010 study showing adjuvant . | October 15, 2021
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant settingApproval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival